337 related articles for article (PubMed ID: 25753065)
1. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.
Mosna F; Papayannidis C; Martinelli G; Di Bona E; Bonalumi A; Tecchio C; Candoni A; Capelli D; Piccin A; Forghieri F; Bigazzi C; Visani G; Zambello R; Zanatta L; Volpato F; Paolini S; Testoni N; Gherlinzoni F; Gottardi M
Am J Hematol; 2015 Jun; 90(6):515-23. PubMed ID: 25753065
[TBL] [Abstract][Full Text] [Related]
2. Core binding factor acute myeloid leukaemia and c-KIT mutations.
Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
[TBL] [Abstract][Full Text] [Related]
3. Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial.
Choi EJ; Lee JH; Kim H; Choi Y; Lee WS; Lee SM; Park JH; Park HS; Lee JH; Lee KH;
Int J Hematol; 2021 Jun; 113(6):851-860. PubMed ID: 33655416
[TBL] [Abstract][Full Text] [Related]
4. [Clinical and cytogenetic features and their influencing factors of core binding factor acute myeloid leukemia].
Li W; Mi YC; Liu BC; Zhou CL; Lin D; Wang HJ; Liu XP; Li QH; Bian SG; Wang JX
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2011 Oct; 33(5):517-24. PubMed ID: 22338135
[TBL] [Abstract][Full Text] [Related]
5. Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.
Hospital MA; Prebet T; Bertoli S; Thomas X; Tavernier E; Braun T; Pautas C; Perrot A; Lioure B; Rousselot P; Tamburini J; Cluzeau T; Konopacki J; Randriamalala E; Berthon C; Gourin MP; Recher C; Cahn JY; Ifrah N; Dombret H; Boissel N
Blood; 2014 Aug; 124(8):1312-9. PubMed ID: 25006122
[TBL] [Abstract][Full Text] [Related]
6. Different prognostic effects of core-binding factor positive AML with Korean AML registry data.
Shin HJ; Min WS; Min YH; Cheong JW; Lee JH; Kim IH; Hong DS; Ahn JS; Kim HJ; Lee WS; Jung CW; Jang JH; Park Y; Kim HJ;
Ann Hematol; 2019 May; 98(5):1135-1147. PubMed ID: 30758645
[TBL] [Abstract][Full Text] [Related]
7. Long-term results of a prospective randomized trial evaluating G-CSF priming in intensive induction chemotherapy followed by autologous stem cell transplantation in elderly patients with acute myeloid leukemia.
Bug G; Koschmieder S; Krauter J; Heuser M; Thol F; Wiebe S; Hofmann WK; Klein SA; Wegener G; Göhring G; Heit W; Hoelzer D; Ganser A; Ottmann OG
Ann Hematol; 2014 Feb; 93(2):193-202. PubMed ID: 23978944
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: a comprehensive large-scale study from a single Chinese center.
Qin YZ; Zhu HH; Jiang Q; Jiang H; Zhang LP; Xu LP; Wang Y; Liu YR; Lai YY; Shi HX; Jiang B; Huang XJ
Leuk Res; 2014 Dec; 38(12):1435-40. PubMed ID: 25449688
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcomes of de novo acute myeloid leukemia in Thai patients.
Niparuck P; Chuncharunee S; Ungkanont A; Udomtrupayakul U; Aungchaisuksiri P; Rerkamnuatchoke B; Jootar S; Atichartakarn V
J Med Assoc Thai; 2009 Sep; 92(9):1143-9. PubMed ID: 19772172
[TBL] [Abstract][Full Text] [Related]
10. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant.
Ahn JS; Kim JY; Kim HJ; Kim YK; Lee SS; Jung SH; Yang DH; Lee JJ; Kim NY; Choi SH; Minden MD; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim DD
Ann Hematol; 2016 Jan; 95(2):301-10. PubMed ID: 26537612
[TBL] [Abstract][Full Text] [Related]
11. [A multivariate model for predicting induction response and prognosis in core binding factor acute myeloid leukemia].
Wang B; Hua XY; Lin RR; Yang B; Wu W; He B; Zhang XW; Xing SS; Li HQ
Zhonghua Nei Ke Za Zhi; 2019 Nov; 58(11):796-802. PubMed ID: 31665853
[No Abstract] [Full Text] [Related]
12. KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement.
Kim HJ; Ahn HK; Jung CW; Moon JH; Park CH; Lee KO; Kim SH; Kim YK; Kim HJ; Sohn SK; Kim SH; Lee WS; Kim KH; Mun YC; Kim H; Park J; Min WS; Kim HJ; Kim DH;
Ann Hematol; 2013 Jan; 92(2):163-71. PubMed ID: 23053179
[TBL] [Abstract][Full Text] [Related]
13. D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
Yui S; Kurosawa S; Yamaguchi H; Kanamori H; Ueki T; Uoshima N; Mizuno I; Shono K; Usuki K; Chiba S; Nakamura Y; Yanada M; Kanda J; Tajika K; Gomi S; Fukunaga K; Wakita S; Ryotokuji T; Fukuda T; Inokuchi K
Ann Hematol; 2017 Oct; 96(10):1641-1652. PubMed ID: 28762080
[TBL] [Abstract][Full Text] [Related]
14. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
15. BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients.
Damiani D; Tiribelli M; Franzoni A; Michelutti A; Fabbro D; Cavallin M; Toffoletti E; Simeone E; Fanin R; Damante G
Am J Hematol; 2013 Oct; 88(10):848-52. PubMed ID: 23760853
[TBL] [Abstract][Full Text] [Related]
16. Cytogenetic risk grouping by the monosomal karyotype classification is superior in predicting the outcome of acute myeloid leukemia undergoing allogeneic stem cell transplantation in complete remission.
Hemmati PG; Schulze-Luckow A; Terwey TH; le Coutre P; Vuong LG; Dörken B; Arnold R
Eur J Haematol; 2014 Feb; 92(2):102-10. PubMed ID: 24138573
[TBL] [Abstract][Full Text] [Related]
17. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
Prébet T; Boissel N; Reutenauer S; Thomas X; Delaunay J; Cahn JY; Pigneux A; Quesnel B; Witz F; Thépot S; Ugo V; Terre C; Recher C; Tavernier E; Hunault M; Esterni B; Castaigne S; Guilhot F; Dombret H; Vey N; ; ;
J Clin Oncol; 2009 Oct; 27(28):4747-53. PubMed ID: 19720919
[TBL] [Abstract][Full Text] [Related]
18. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.
Bloomfield CD; Lawrence D; Byrd JC; Carroll A; Pettenati MJ; Tantravahi R; Patil SR; Davey FR; Berg DT; Schiffer CA; Arthur DC; Mayer RJ
Cancer Res; 1998 Sep; 58(18):4173-9. PubMed ID: 9751631
[TBL] [Abstract][Full Text] [Related]
19. Stratification of de novo adult acute myelogenous leukemia with adverse-risk karyotype: can we overcome the worse prognosis of adverse-risk group acute myelogenous leukemia with hematopoietic stem cell transplantation?
Yoon JH; Kim HJ; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW
Biol Blood Marrow Transplant; 2014 Jan; 20(1):80-8. PubMed ID: 24149098
[TBL] [Abstract][Full Text] [Related]
20. [Prognosis and chromosomal abnormalities in 79 children with t (8;21) acute myeloid leukemia].
Chen YM; Liu TF; Ruan M; Zou Y; Chen XJ; Guo Y; Wang SC; Zhu XF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):542-6. PubMed ID: 19968066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
